文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

冈比亚母亲B组链球菌疫苗的潜在成本效果

Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia.
PubMed 文献 · Vaccine · 2020-03-05

研究构建静态决策分析成本效果模型,从医疗服务提供者视角评估冈比亚六价B组链球菌(GBS)母亲疫苗接种项目的新生儿健康收益与成本。模拟疫苗效力50-90%,与现行标准照护相比,接种可避免24例GBS疾病(55%)和768个伤残调整生命年;当疫苗效力70%时,每剂最高12美元(2016年美元)具有成本效果,每剂最高3美元则极具成本效果。

要点

  • 与现行标准照护相比,六价GBS疫苗接种可避免24例GBS疾病(55%)和768个伤残调整生命年。
  • 当疫苗效力70%时,每剂最高12美元(2016年美元)具有成本效果,每剂最高3美元则极具成本效果。
  • 每剂12美元时,冈比亚孕妇年度队列的疫苗接种总成本为1,056,962美元。

核心结论

  • 引入六价GBS疫苗将大幅降低冈比亚当前GBS疾病负担,但每剂疫苗价格需在12美元或以下才具有成本效果。

研究设计与样本

  • 研究构建静态决策分析成本效果模型,从医疗服务提供者视角进行评估。
  • 人口学数据和急性照护成本来自2012-2015年冈比亚研究,其他模型参数来自联合国和世界卫生组织来源,并补充全球GBS系统综述和文献检索数据。
  • 由于疫苗效力未知,模拟了50-90%的疫苗效力估计值;成本以美元报告,成本效果阈值采用冈比亚GDP的1倍(473美元,极具成本效果)和3倍(1420美元,具有成本效果)。

主要发现

  • 与现行标准照护(无预防GBS疾病的干预措施)相比,接种六价疫苗可避免24例GBS疾病(55%)和768个伤残调整生命年。
  • 当疫苗效力70%时,每剂最高12美元(2016年美元)具有成本效果,每剂最高3美元则极具成本效果。
  • 每剂12美元时,冈比亚孕妇一个年度队列的疫苗接种总成本为1,056,962美元。
  • 单因素敏感性分析显示,GBS发病率是成本效果比最具影响力的参数。

关键数值与推荐

  • 成本效果阈值采用冈比亚GDP的1倍(473美元,极具成本效果)和3倍(1420美元,具有成本效果)。
  • 模拟疫苗效力为50-90%。

临床怎么用

  • 作者结论认为,引入六价疫苗将大幅降低冈比亚当前GBS疾病负担,但每剂疫苗价格需在12美元或以下才具有成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate neonatal health benefits and healthcare provider costs of a theoretical Group B streptococcal (GBS) hexavalent maternal vaccination programme in The Gambia, a low-income setting in West Africa. METHODS: A static decision analytic cost-effectiveness model was developed from the healthcare provider perspective. Demographic data and acute care costs were available from studies in The Gambia undertaken in 2012-2015. Further model parameters were taken from United Nations and World Health Organisation sources, supplemented by data from a global systematic review of GBS and literature searches. As vaccine efficacy is not known, we simulated vaccine efficacy estimates of 50-90%. Costs are reported in US dollars. Cost-effectiveness thresholds of one (US$473, very cost effective) and three (US$1420, cost effective) times Gambian GDP were used. RESULTS: Vaccination with a hexavalent vaccine would avert 24 GBS disease cases (55%) and 768 disability adjusted life years compared to current standard of care (no interventions to prevent GBS disease). At vaccine efficacy of 70%, the programme is cost-effective at a maximum vaccine price per dose of 12 US$ (2016 US$), and very cost-effective at a maximum of $3/dose. The total costs of vaccination at $12 is $1,056,962 for one annual cohort of Gambian pregnant women. One-way sensitivity analysis showed that GBS incidence was the most influential parameter on the cost effectiveness ratio. CONCLUSION: The introduction of a hexavalent vaccine would considerably reduce the current burden of GBS disease in The Gambia but to be cost-effective, the vaccine price per dose would need to be $12/dose or less.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ahmed N, Giorgakoudi K, Usuf E, et al. Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia. Vaccine. 2020. PMID: 32147298. doi:10.1016/j.vaccine.2020.02.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。